Drug facts

The benefits of semaglutide

By David Chen·Editor·Reviewed September 2026

What the labels approve¹

An indication is the strongest claim there is: a trial measured the condition as an endpoint, and a regulator reviewed the result. Section 1 of the Wegovy label, in its own words:

WEGOVY® injection is indicated in combination with a reduced calorie diet and increased physical activity:

• To reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight.
• To reduce excess body weight and maintain weight reduction long term in:
  • Adults and pediatric patients aged 12 years and older with obesity.
  • Adults with overweight in the presence of at least one weight-related comorbid condition.
• For the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults. This indication is approved under accelerated approval based on improvement of MASH and fibrosis. Continued approval for this indication may be contingent upon the verification and description of clinical benefit in a confirmatory trial.

And section 1 of the Ozempic label, which is the same molecule approved for type 2 diabetes:²

OZEMPIC® is indicated:

• as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
• to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.
• to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease.

The Wegovy tablet carries the first two of those three — cardiovascular risk reduction and weight reduction in adults — and not the MASH indication. What the tablet is, and what sellers mean when they say “oral semaglutide”, is on the pill against the injection.

The heart, in obesity³

The cardiovascular indication rests on SELECT, which enrolled 17,604 adults aged 45 and older who had existing cardiovascular disease and a body-mass index of 27 or more, and no history of diabetes. They were assigned to semaglutide 2.4 mg weekly or placebo, on top of standard care, and followed for a mean of 39.8 months. As the trial report states it:

The hazard ratio was 0.80, with a 95% confidence interval of 0.72 to 0.90 — a 20% lower rate of that combined endpoint over roughly three and a half years, in that population, against placebo. Three things the label is careful about are worth carrying over. Superiority was not confirmed for cardiovascular death on its own; all-cause death was not statistically significant under the trial’s prespecified testing order; and on heart failure the label’s footnote to that table says flatly: “Effect on heart failure has not been established.”

The same trial is the longest safety record semaglutide has, and it is not a one-sided document: 16.6% of the semaglutide group stopped the drug because of an adverse event against 8.2% on placebo. That side of it is on long-term safety, along with what the label reports about gallbladder disease — and the label also reports more hip and pelvis fractures in two groups in this trial, which is on bone density.

Heart and kidneys, in diabetes⁵

Ozempic’s two outcome indications come from two trials, both in people with type 2 diabetes, both against placebo on top of standard care.

FLOW randomized 3,533 adults who had type 2 diabetes and chronic kidney disease to semaglutide 1.0 mg weekly or placebo, with a median follow-up of 3.4 years; it was stopped early at a planned interim analysis. The primary outcome — kidney failure, a 50% fall in eGFR, or death from kidney or cardiovascular causes — occurred 331 times in the semaglutide group against 410 on placebo (hazard ratio 0.76, 95% CI 0.66 to 0.88). Death from cardiovascular causes was lower (0.71, 0.56 to 0.89), the annual eGFR slope was less steep by 1.16 mL per minute per 1.73 m², and all-cause death was 20% lower (0.80, 0.67 to 0.95). The label adds one subgroup caution: the benefit on the primary endpoint “was not evident in patients taking SGLT2 inhibitors at baseline, but there were few events in these patients”.

SUSTAIN 6 randomized 3,297 adults with type 2 diabetes at high cardiovascular risk to semaglutide 0.5 or 1.0 mg weekly or placebo for 104 weeks, and was designed to test noninferiority. The combined endpoint of cardiovascular death, non-fatal heart attack or non-fatal stroke occurred in 6.6% on semaglutide against 8.9% on placebo (hazard ratio 0.74, 95% CI 0.58 to 0.95).⁴ Non-fatal stroke was lower (1.6% against 2.7%); rates of cardiovascular death were similar. The same trial is where semaglutide’s retinopathy warning comes from: complications of diabetic retinopathy were significantly more common on semaglutide (hazard ratio 1.76, 95% CI 1.11 to 2.78).

Neither result transfers to people without type 2 diabetes. There is no kidney indication on Wegovy and no kidney outcomes trial of semaglutide in people without diabetes.

The liver⁶

The MASH indication comes from ESSENCE, a 240-week trial whose first reported analysis covered 800 patients with biopsy-defined MASH and stage 2 or 3 fibrosis at week 72, randomized two-to-one to semaglutide 2.4 mg weekly or placebo.

Read the placebo column before the other one: a third of the placebo group met the first endpoint too, which is what a liver biopsy scored twice can do. The endpoints are histology — what a pathologist sees in tissue — not whether anyone avoided liver failure or lived longer. That is exactly why the approval is an accelerated one, and why the label says continued approval “may be contingent upon the verification and description of clinical benefit in a confirmatory trial”. The trial itself runs to 240 weeks for that reason.

Weight, blood pressure and lipids¹

Weight is the approved one, and the number is on STEP 1: 14.9% of body weight over 68 weeks on semaglutide 2.4 mg, against 2.4% on placebo, in 1,961 adults with obesity or overweight and no diabetes.⁷ Whether a compounded vial delivers that is a different question, and the honest answer is on does compounded semaglutide work?

The same trial measured blood pressure and lipids, and the label reports them for that study. These are secondary measurements, outside the trial’s prespecified statistical testing, and none of them is an approved use: semaglutide is not approved to treat high blood pressure or high cholesterol.

The last row is in the same table as the other five, and it moves the other way. A resting heart rate that rises by a few beats a minute is why the label asks prescribers to monitor it, and it is a reminder that a cardiometabolic panel is not a list of improvements with the inconvenient line left out.

Alzheimer’s disease⁸

This one has an answer, and it is no. EVOKE and EVOKE+ randomized 3,808 people aged 55 to 85 with amyloid-confirmed early Alzheimer’s disease — mild cognitive impairment or mild dementia — to oral semaglutide at up to 14 mg daily or placebo, for up to 156 weeks. The primary endpoint was the change in a standard dementia rating, CDR-SB, at week 104. In EVOKE the change was 2.3 on semaglutide against 2.3 on placebo; in EVOKE+ it was 2.2 against 2.1. Neither difference approached significance (p = 0.57 and p = 0.46). The published conclusion: “Oral semaglutide was not efficacious in slowing clinical progression in participants with early Alzheimer’s disease.” Both trials were discontinued.

Two details keep this from being read too widely. The drug tested was the tablet, not the weekly injection, and the participants already had Alzheimer’s disease — the trials asked whether semaglutide slows established disease, not whether anything about it affects who develops dementia in the first place. That second question remains open, and a page claiming an answer to it is not reading these trials.

What is not approved¹

• Obstructive sleep apnea. Not a semaglutide indication at any dose — that approval belongs to the other molecule, as sleep apnea sets out.
• Heart failure. The Wegovy label’s own footnote to the SELECT table: effect on heart failure has not been established.
• Kidney disease without type 2 diabetes. The kidney indication and the trial behind it are both confined to people who have type 2 diabetes and chronic kidney disease.
• Early Alzheimer’s disease. Tested, and the result was negative.
• Anything a seller adds to the vial. B12, B6 and glycine carry no semaglutide indication and no trial of their own here — see what else is in the vial.

What this page is not

Indications are quoted from section 1 of each current label, and every trial result is stated with its population, dose and comparator; where a result is not an approved use, the page says so. None of it is a prediction about you, and whether semaglutide is the right drug for any of these conditions is a prescriber’s decision. See the medical disclaimer, and side effects for the other column of the ledger.